Abstract
Background
Despite the literature indicating adverse interactions between warfarin and cytotoxic agents, whether such an interaction occurs when warfarin and gefitinib are used concomitantly is unknown. We analyzed the prevalence of the concomitant use of warfarin and gefitinib, and the incidence of prothrombin time-international normalized ratio (PT-INR) alterations or adverse interactions in concomitant users of warfarin and gefitinib.
Methods
We conducted a retrospective study of patients with non-small cell lung cancer treated at the Kitasato University Hospital who received concomitant warfarin and gefitinib between September 2002 and January 2007. Medical information, including the indication for warfarin use, warfarin dosing and dosing changes, and exposure to gefitinib were collected from computerized databases and medical records.
Results
Twelve (4.1%) of 296 patients treated with gefi— tinib received warfarin. PT-INR elevation occurred in 6 patients (50.0%). Two (16.7%) of the 12 patients had liver metastases. Liver dysfunction was associated with PT-INR elevation (P = 0.0100).
Conclusion
As there is a possibility of PT-INR abnormalities occurring during the concomitant use of gefitinib and warfarin, clinicians should be aware of this interaction. Because of the potentially severe consequences of this interaction, close monitoring of PT-INR and warfarin dose adjustment are recommended for patients receiving warfarin and gefitinib, especially during the first 2 weeks in the beginning of warfarin therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brown MC (1999) An adverse interaction between warfarin and 5-fluorouracil: a case report and review of the literature. Chemotherapy 45:392–395
Cohen MH, Williams GA, Sridhara R, et al. (2004) United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10:1212–1218
Cropp JS, Bussey HI (1997) A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 17:917–928
Douillard J-Y, Kim ES, Hirsh V, et al. (2007) Phase III, randomized, open-label, parallel-group study of oral gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic non small cell lung cancer who have previously received platinum-based chemotherapy (INTEREST). Eur J Cancer 43(Suppl 5):2
Fukuoka M, Yano S, Giaccone G, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21:2237–2246
Hall G, Lind MJ, Huang M, et al. (1990) Intravenous infusions of ifosfamide/mesna and perturbation of warfarin anticoagulant control. Postgrad Med J 66:860–861
Kris MG, Natale RB, Herbst RS, et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158
Le AT, Hasson NK, Lum BL (1997) Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy. Ann Pharmacother 31:1006–1008
Li J, Brahmer J, Messersmith W, et al. (2006) Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs 24:291–297
Marshall J (2006) Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107:1207–1218
Michalets EL (1998) Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18:84–112
Mousa SA (2006) Role of current and emerging antithrombotics in thrombosis and cancer. Drugs Today (Barc) 42:331–350
O’Reilly RA, Aggeler PM, Leong LS (1963) Studies on the coumarin anticoagulant drugs: the pharmacodynamics of warfarin in man. J Clin Invest 42:1542–1551
Onoda S, Mitsufuji H, Yanase N, et al. (2005) Drug interaction between gefitinib and warfarin. Jpn J Clin Oncol 35:478–482
Sallah S, Wan JY, Nguyen NP (2002) Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 87:575–579
Scarfe MA, Israel MK (1994) Possible drug interaction between warfarin and combination of levamisole and fluorouracil. Ann Pharmacother 28:464–467
Serlin MJ, Breckenridge AM (1983) Drug interactions with warfarin. Drugs 25:610–620
Thatcher N, Chang A, Parikh P, et al. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527–1537
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Arai, S., Mitsufuji, H., Nishii, Y. et al. Effect of gefitinib on warfarin antithrombotic activity. Int J Clin Oncol 14, 332–336 (2009). https://doi.org/10.1007/s10147-008-0871-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-008-0871-2